Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss.

To optimize strategies that mitigate the risk of graft loss associated with HLA incompatibility, we evaluated whether sequence defined HLA targets (eplets) that result in donor-specific antibodies are associated with transplant outcomes. To define this, we fit multivariable Cox proportional hazard models in a cohort of 118 382 United States first kidney transplant recipients to assess risk of death-censored graft failure by increments of ten antibody-verified eplet mismatches. To verify robustness of our findings, we conducted sensitivity analysis in this United States cohort and assessed the role of antibody-verified eplet mismatches as autonomous predictors of transplant glomerulopathy in an independent Canadian cohort. Antibody-verified eplet mismatches were found to be independent predictors of death-censored graft failure with hazard ratios of 1.231 [95% confidence interval 1.195, 1. 268], 1.268 [1.231, 1.305] and 1.411 [1.331, 1.495] for Class I (HLA-A, B, and C), -DRB1 and -DQB1 loci, respectively. To address linkage disequilibrium between HLA-DRB1 and -DQB1, we fit models in a subcohort without HLA-DQB1 eplet mismatches and found hazard ratios for death-censored graft failure of 1.384 [1.293, 1.480] for each additional antibody-verified HLA-DRB1 eplet mismatch. In a subcohort without HLA-DRB1 mismatches, the hazard ratio was 1.384 [1.072, 1.791] for each additional HLA-DQB1 mismatch. In the Canadian cohort, antibody-verified eplet mismatches were independent predictors of transplant glomerulopathy with hazard ratios of 5.511 [1.442, 21.080] for HLA-DRB1 and 3.640 [1.574, 8.416] for -DRB1/3/4/5. Thus, donor-recipient matching for specific HLA eplets appears to be a feasible and clinically justifiable strategy to mitigate risk of graft loss.

[1]  S. Takemoto,et al.  Landsteiner Award. HLA epitope matching , 1992, Transfusion.

[2]  F. Claas,et al.  Novel aspects of epitope matching and practical application in kidney transplantation. , 2017, Kidney international.

[3]  P W Nickerson,et al.  The Synergistic Effect of Class II HLA Epitope‐Mismatch and Nonadherence on Acute Rejection and Graft Survival , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  M. Kramer,et al.  Analysis of 'sensitive' periods of fetal and child growth. , 2019, International journal of epidemiology.

[5]  P W Nickerson,et al.  Class II HLA Epitope Matching—A Strategy to Minimize De Novo Donor‐Specific Antibody Development and Improve Outcomes , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  M. Bots,et al.  Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  F. Claas,et al.  Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients. , 2017, Kidney international.

[8]  D. Wishart,et al.  Transplant Glomerulopathy, Late Antibody‐Mediated Rejection and the ABCD Tetrad in Kidney Allograft Biopsies for Cause , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  S. Keshavjee,et al.  Identification of risk epitope mismatches associated with de novo donor‐specific HLA antibody development in cardiothoracic transplantation , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  T. Larson,et al.  Transplant Glomerulopathy: Subclinical Incidence and Association with Alloantibody , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  J. Gralla,et al.  The Impact of Human Leukocyte Antigen Mismatching on Sensitization Rates and Subsequent Retransplantation After First Graft Failure in Pediatric Renal Transplant Recipients , 2013, Transplantation.

[12]  Hongzhe Li,et al.  HLA Amino Acid Polymorphisms and Kidney Allograft Survival , 2017, Transplantation.

[13]  M. Stegall,et al.  The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  R. Colvin,et al.  Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. , 2011, Kidney international.

[15]  P. Nickerson,et al.  Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. , 2017, Journal of the American Society of Nephrology : JASN.

[16]  H. V. van Houwelingen,et al.  A regression model with unexplained residuals was preferred in the analysis of the fetal origins of adult diseases hypothesis. , 2005, Journal of clinical epidemiology.

[17]  S. Kim,et al.  Living donor age and kidney transplant outcomes: an assessment of risk across the age continuum , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[18]  A Laupacis,et al.  HLA‐DR and ‐DQ Eplet Mismatches and Transplant Glomerulopathy: A Nested Case–Control Study , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  R. Martorell,et al.  Size at birth, weight gain in infancy and childhood, and adult blood pressure in 5 low- and middle-income-country cohorts: when does weight gain matter?123 , 2009, The American journal of clinical nutrition.

[20]  K. Oualkacha,et al.  Inaccuracies in epitope repertoire estimations when using multilocus allele‐level HLA genotype imputation tools , 2018, HLA.

[21]  R. Montgomery,et al.  Transplanting the highly sensitized patient: trials and tribulations , 2013, Current opinion in nephrology and hypertension.

[22]  J. Friedewald,et al.  Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  S. J. H. do Monte,et al.  First report on the antibody verification of HLA-DR, HLA-DQ and HLA-DP epitopes recorded in the HLA Epitope Registry. , 2014, Human immunology.

[24]  P. Gourraud,et al.  Validation of statistical imputation of allele-level multilocus phased genotypes from ambiguous HLA assignments. , 2014, Tissue antigens.

[25]  F. Christiansen,et al.  Modeling the Benefits and Costs of Integrating an Acceptable HLA Mismatch Allocation Model for Highly Sensitized Patients , 2014, Transplantation.

[26]  M. Marrari,et al.  16th IHIW: A Website for Antibody‐Defined HLA Epitope Registry , 2012, International journal of immunogenetics.

[27]  Loren Gragert,et al.  Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. , 2013, Human immunology.

[28]  R. Duquesnoy.  Update of the HLA class I eplet database in the website based registry of antibody-defined HLA epitopes. , 2014, Tissue antigens.

[29]  A. Matas,et al.  Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  H. Cardinal,et al.  Association of Sex with Risk of Kidney Graft Failure Differs by Age. , 2017, Journal of the American Society of Nephrology : JASN.

[31]  G. Russ,et al.  The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation , 2016, Transplantation direct.

[32]  J. Schafer.  Multiple imputation: a primer , 1999, Statistical methods in medical research.

[33]  M. Haas.  The relationship between pathologic lesions of active and chronic antibody‐mediated rejection in renal allografts , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.